Erasca, Inc. (ERAS) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $31.00K; Additional Paid in Capital, Common StockUSD $1.48B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.25M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $31.00K; Additional Paid in Capital, Common StockUSD $1.47B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-699.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $28.00K; Additional Paid in Capital, Common StockUSD $1.22B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $628.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $28.00K; Additional Paid in Capital, Common StockUSD $1.21B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $649.00K.
Erasca, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $31.00K | $1.48B | $-1.25M | $-1.12B | $361.87M | 3 month · $9.61M |
| 2026-03-31 | (m) | $31.00K | $1.47B | $-699.00K | $-1.08B | $393.53M | 3 month · $8.46M |
| 2025-12-31 | $0.00 | $28.00K | $1.22B | $628.00K | $-892.21M | $325.17M | 12 month · $24.90M |
| 2025-09-30 | (m) | $28.00K | $1.21B | $649.00K | $-863.12M | $347.89M | 3 month · $5.96M |
| 2025-06-30 | (m) | $28.00K | $1.20B | $415.00K | $-832.50M | $372.26M | 3 month · $6.40M |
| 2025-03-31 | (m) | $28.00K | $1.20B | $628.00K | $-798.63M | $399.50M | 3 month · $6.71M |
| 2024-12-31 | $0.00 | $28.00K | $1.19B | $405.00K | $-767.66M | $423.50M | 12 month · $26.97M |
| 2024-09-30 | (m) | $28.00K | $1.18B | $1.82M | $-735.43M | $450.04M | 3 month · $6.64M |
| 2024-06-30 | (m) | $27.00K | $1.16B | $-196.00K | $-704.23M | $451.09M | 3 month · $7.18M |
| 2024-03-31 | (m) | $15.00K | $929.63M | $-210.00K | $-641.03M | $288.41M | 3 month · $6.85M |
| 2023-12-31 | $0.00 | $15.00K | $922.61M | $77.00K | $-606.01M | $316.69M | 12 month · $26.23M |
| 2023-09-30 | (m) | $15.00K | $915.85M | $-575.00K | $-576.31M | $338.98M | 3 month · $6.24M |
| 2023-06-30 | (m) | $15.00K | $909.43M | $-793.00K | $-545.95M | $362.70M | 3 month · $7.01M |
| 2023-03-31 | (m) | $15.00K | $901.12M | $-514.00K | $-514.17M | $386.45M | 3 month · $6.84M |
| 2022-12-31 | (m) | $15.00K | $893.85M | $-1.04M | $-480.97M | $411.85M | 12 month · $20.11M |
| 2022-09-30 | (m) | $12.00K | $712.41M | $-1.38M | $-345.72M | $365.32M | 3 month · $5.23M |
| 2022-06-30 | (m) | $12.00K | $706.51M | $-1.22M | $-310.23M | $395.07M | 3 month · $5.05M |
| 2022-03-31 | (m) | $12.00K | $700.23M | $-951.00K | $-274.62M | $424.66M | 3 month · $4.44M |
| 2021-12-31 | (m) | $12.00K | $694.84M | $-162.00K | $-238.17M | $456.53M | 12 month · $8.33M |
| 2021-09-30 | (m) | $12.00K | $690.68M | (m) | $-207.70M | $482.99M | 3 month · $3.02M |
| 2021-06-30 | (m) | $3.00K | $11.63M | $-1.00K | $-161.63M | $-150.00M | 3 month · $1.64M |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | $-129.26M | 3 month · $795.00K |
| 2020-12-31 | (m) | $3.00K | $1.41M | $2.00K | $-115.40M | $-113.98M | 12 month · $797.00K |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | $-52.82M | 3 month · $176.00K |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $-42.55M | 3 month · $109.00K |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $-37.18M | 3 month · $105.00K |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $-13.60M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |